loading page

Progressive liver injury and increased mortality risk in COVID-19 patients: a retrospective cohort study in China
  • +17
  • Shuisheng Zhang,
  • Li Dong,
  • Gaoming Wang,
  • Yuan Tian,
  • Xiaofang Ye,
  • Yue Zhao,
  • Zhengyin Liu,
  • Jiayu Zhai,
  • Zhiling Zhao,
  • Junhong Wang,
  • Huimin Zhang,
  • Xiaolong Li,
  • Changxin Wu,
  • Caiting Yang,
  • Lijuan Yang,
  • Haixia Du,
  • Hui Wang,
  • Qinggang Ge,
  • Dianrong Xiu,
  • Ning Shen
Shuisheng Zhang
Author Profile
Gaoming Wang
Author Profile
Xiaofang Ye
Author Profile
Zhengyin Liu
Author Profile
Jiayu Zhai
Author Profile
Zhiling Zhao
Author Profile
Junhong Wang
Author Profile
Huimin Zhang
Author Profile
Xiaolong Li
Author Profile
Changxin Wu
Author Profile
Caiting Yang
Author Profile
Lijuan Yang
Author Profile
Qinggang Ge
Author Profile
Dianrong Xiu
Author Profile

Abstract

Background: Liver injury is common and also can be fatal, particularly in severe or critical patients with coronavirus disease 2019 (COVID-19). However, there is lack of an in-depth investigation into the risk factors of liver injury and into the effective measures to prevent subsequent mortality risk. Methods: A retrospective cohort study of 440 consecutive patients with relatively severe COVID-19 between January 28 and March 9, 2020 in Tongji Hospital, Wuhan, China was performed. Data on clinical features, laboratory parameters, medications and prognosis were collected. Results: COVID-19-associated liver injury more frequently occurred in patients aged ≥65 years, or female, or with other comorbidities, decreased lymphocyte count, elevated D-dimer or serum ferritin (all p values<0.05). The disease severity of COVID-19 was an independent risk factors of livery injury (OR 2.86; 95% CI 1.78 to 4.59 in severe patients and 13.44; 95% CI, 7.21 to 25.97 in critical patients). The elevated levels of on-admission aspartate aminotransferase (AST) and total bilirubin (TBIL) indicated the increased mortality risk (both p values <0.001). Using intravenous nutrition or antibiotics increased risk of COVID-19-associated liver injury. Hepatoprotective drugs tended to be of assistance to treat the liver injury and improve the prognosis of patients with COVID-19-associated liver injury. Conclusions: More intensive monitoring with AST or TBIL is recommended for COVID-19 patients, especially aged ≥65 years, or female, or with other comorbidities. Drug hepatotoxicity of antibiotics and intravenous nutrition should be alert for COVID-19 patients.